CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase I drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CD30’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD30 overview

Gene therapy is under development for the treatment of adult T-cell leukemia/lymphoma, anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, NK/T-cell lymphoma, peripheral T-cell lymphoma, enteropathy-associated T cell lymphoma, Burkitt lymphoma, Hodgkin lymphoma, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma and mycosis fungoides. It is administered as an infusion through parenteral route and intravenous route. The therapeutic candidate constitutes autologous T cells genetically modified by lentivirus vector encoding 3rd generation anti-CD30 CAR. It acts by targeting tumor cells expressing CD30.

Wuhan Bio-Raid Biotechnology overview

Wuhan Bio-Raid Biotechnology is a developer of CAR-T cell immunotherapy that promotes cellular immunotherapy technology to clinical application. The company is headquartered in China.

For a complete picture of CD30’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.